Bristol-Myers Squibb Company announced that it has completed the previously announced planned acquisition of Padlock Therapeutics, Inc.

The transaction includes full rights to Padlock’s Protein/Peptidyl Arginine Deiminase inhibitor discovery programme focused on the development of potentially transformational treatment approaches for patients with rheumatoid arthritis and other autoimmune diseases.

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.